薛玉文靶向治疗沂南2.pptVIP

ISEL (IRESSA Survival Evaluation in Lung cancer), a randomised, double-blind, placebo-controlled, parallel-group, multicentre, Phase III trial, was designed to investigate the effect on survival of gefitinib 250 mg/day plus best supportive care (BSC) in patients with NSCLC who were refractory to, or intolerant of, their most recent chemotherapy regimen.1 The primary endpoint of ISEL was survival in the overall and adenocarcinoma patient populations. Secondary endpoints included time to treatment failure (TTF), ORR, QoL and symptom improvement and safety. Eligible patients were 18 years old, h